Deutsche Bank has maintained a Buy rating on Eli Lilly, setting a price target of $1,010, as the pharmaceutical giant plans to invest over $50 billion in U.S. manufacturing, marking the largest investment in the sector's history. This expansion includes four new facilities aimed at enhancing production capabilities, particularly in the high-demand Diabesity sector, where Eli Lilly has seen a 32% revenue growth over the past year. Analysts from JPMorgan and BMO Capital Markets have also reaffirmed positive ratings, highlighting the company's strategic initiatives and upcoming clinical trial results.